Igenica, Inc. Enrolls First Patient In Phase 1 Study Of IGN523 In Acute Myeloid Leukemia
Published: Mar 18, 2014
BURLINGAME, Calif.--(BUSINESS WIRE)--Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML). The trial is designed to assess the safety, pharmacokinetics and clinical activity of IGN523, an antibody targeting CD98, a cell surface protein frequently overexpressed on AML cells.
Help employers find you! Check out all the jobs and post your resume.